Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Dyslipidemia Drugs Market $48 Billion by 2027

The global market for dyslipidemia drugs predicted to reach $48 billion by 2027, increasing at a CAGR of 9.9% over the forecast period, driven by an increasing overall patient numbers and sales growth for the newer and effective add-on therapies.

  • Furthermore, the high cost of PCSK9 inhibitors would contribute to increasing revenue growth, and the PCSK9 inhibitors are being positioned as add-on therapies to statins, or as alternative therapies for statin-intolerant patients.
    • In the longer term, the dyslipidemia market could be further bolstered by late-phase pipeline molecules, bempedoic acid as well as inclisiran, which are expected to provide physicians and patients additional options for lowering LDL-C levels.
Global Dyslipidemia Drugs Market

However, the main reasons for the declining market trend include patent expiries of key brands as well as the add-on therapies have not been able to clearly demonstrate a benefit in addition to statin therapy in cardiovascular outcomes trials, leading to the loss of patient share. At the same time, several agents used for the prevention and treatment of vascular diseases have an adverse effect on the lipid profile.

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease, but has historically been underdiagnosed in patients because of its asymptomatic nature and the lack of screening programs across the world.

  • Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and major health care burden in worldwide regardless of different ethnicities. Dyslipidemia is a major vascular risk factor.
    • Dyslipidemia is characterized by high levels of atherogenic lipoproteins including low density lipoprotein cholesterol (LDL-C), is considered as the major risk factor of ASCVD.
      • Dyslipidemia, including high levels of total cholesterol, low-density lipoprotein cholesterol, and triglyceride, and low levels of high-density lipoprotein cholesterol, is a major risk factor of atherosclerosis that leads to various cardiovascular diseases.

According to the World Health Organization (WHO) estimates, the prevalence of dyslipidemia continue to increase in recent decades. Millions of people have a lipid abnormality or dyslipidemia.

  • Given the inherent risk of cardiovascular disease that dyslipidemias carry, multiple prescription therapies are available for modifying lipid levels. In 2016, the US and UK had an estimated 97 million and 27 million cases of hypercholesterolemia, with prevalence expected to top 100 million and 30 million, respectively, by 2023.

The global dyslipidemia drugs market report estimates the market size ($million 2017 to 2027), market share, growth trends forecast (CAGR% 2021 to 2027).

The global market for dyslipidemia drugs segmented by drug class (product/brand) – bile acid resins [Colestid (colestipol), Questran / Locholest / Prevalite (cholestyramine), Welchol (colesevelam)], fibric acid and omega-3 fatty acid derivatives (Fenofibrate, Gemfibrozil, Vascespa), Niacins / vitamin B3 agonist (Niacor, Niaspan, Slo-Niacin), PCSK9 inhibitor [Praluent (alirocumab), Repatha (evolocumab)], Statins / HMG‑CoA reductase inhibitor [Crestor (rosuvastatin), Lescol (fluvastatin), Lipitor (atorvastatin)], Fixed dose combinations [Advicor (lovastatin and niacin), Caduet (atorvastatin and amlodipine), Liptruzet (ezetimibe and atorvastatin), Zetia (ezetimibe), Vytorin (simvastatin and ezetimibe)], pipeline analysis [AMPK stimulant/ATP citrate pro 3S lyase inhibitor (bempedoic acid), apolipoprotein C inhibitor (volanesorsen), cholesterol absorption inhibitor (hyzetimibe), cholesterol ester transfer protein (CETP) antagonist/ CETP inhibitor (anacetrapib), PPAR-α agonist (pemafibrate), vitamin B3 Agonist/ ADP ribose polymerase inhibitor (TRIA-662), and geography.

  • There are also numerous pharmacological options when it comes to the treatment of dyslipidemia.
    • Owing to their low cost due to genericization and strong historical evidence of reducing cardiovascular disease and mortality in high risk patients.
  • Statins accounted for largest share of the dyslipidemia drugs market.
    • Statins are entrenched in the dyslipidemia treatment algorithm for both primary and secondary prevention, but despite their use, a substantial percentage of patients have residual cardiovascular risk, driving the need for new add-on therapies that can be used alongside statin treatment for further risk reduction. 
  • Top mechanisms of action for dyslipidemia drugs in development include HMGCoA reductase inhibitor, Angiotensin II 1 antagonist, PCSK9 inhibitor, cholesterol absorption inhibitor, Niemann-Pick C1-like 1 protein antagonist, L-type calcium channel antagonist, cholesterol inhibitor, cholesterol ester transfer protein antagonist, omega 3 fatty acid stimulant, and peroxisome proliferator-activated receptor alpha agonist (PPAR).
    • In addition, agents belonging to the same class (e.g. beta blockers) can have significantly different actions on lipid levels. However, during the forecast period, the dyslipidemia therapy market is expected to return to growth with the launch of two novel pipeline classes, whereas there are about 25+ new drug candidates in phase III development phase.

The global dyslipidemia therapeutics market research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

The report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

Major competitors operating in the global markettor dyslipidemia therapeutics and included in this report are Abbott Laboratories, Inc., Amgen, Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Esperion Therapeutics, Inc., Ionis Pharmaceuticals, Inc. (Akcea Therapeutics, Inc.), Kowa Pharmaceuticals America, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pelion (Pharmena S.A.), Regeneron Pharmaceuticals, Inc., Sanofi S.A., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan N.V.), and Zhejiang Hisun Pharmaceutical Co., Ltd.

  • Drug Class (Product/Brand)
    • Bile Acid Resins
      • Colestid (Colestipol)
      • Questran / Locholest / Prevalite (Cholestyramine)
      • Welchol (Colesevelam)
    • Fibric Acid and Omega-3 Fatty Acid Derivatives
      • Fenofibrate
      • Gemfibrozil
      • Vascespa
    • Niacins / Vitamin B3 Agonist
      • Niacor
      • Niaspan
      • Slo-Niacin
    • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor
      • Praluent (alirocumab)
      • Repatha (evolocumab)
    • Statins / 3‑hydroxy‑3‑methylglutaryl-coenzyme‑A (HMG‑CoA) Reductase Inhibitor
      • Crestor (rosuvastatin)
      • Lescol (fluvastatin)
      • Lipitor (atorvastatin)
    • Fixed Dose Combinations (FDCs)
      • Advicor (lovastatin and niacin)
      • Caduet (atorvastatin and amlodipine)
      • Liptruzet (ezetimibe and atorvastatin)
      • Zetia (ezetimibe) p
      • Vytorin (simvastatin and ezetimibe)
  • Pipeline Analysis
    • AMPK Stimulant/ATP Citrate Pro 3S Lyase Inhibitor
      • Bempedoic Acid
    • Apolipoprotein C Inhibitor
      • Volanesorsen
    • Cholesterol Absorption Inhibitor
      • Hyzetimibe
    • Cholesterol Ester Transfer Protein (CETP) Antagonist/ CETP Inhibitor
      • Anacetrapib (MK-0859)
    • Peroxisome Proliferator Activated Receptor Alpha (PPAR-α) Agonist
      • Pemafibrate
    • Vitamin B3 Agonist/ ADP Ribose Polymerase Inhibitor
      • TRIA-662
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Amgen, Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Esperion Therapeutics, Inc.
    • Ionis Pharmaceuticals, Inc. (Akcea Therapeutics, Inc.)
    • Kowa Pharmaceuticals America, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Pelion (Pharmena S.A.)
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi S.A.
    • Shionogi & Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc. (Mylan N.V.)
    • Zhejiang Hisun Pharmaceutical Co., Ltd.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/dyslipidemia-drugs-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]